Cite
Moots RJ, Xavier RM, Mok CC, et al. Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS One. 2017;12(6):e0179308doi: 10.1371/journal.pone.0179308.
Moots, R. J., Xavier, R. M., Mok, C. C., Rahman, M. U., Tsai, W. C., Al-Maini, M. H., Pavelka, K., Mahgoub, E., Kotak, S., Korth-Bradley, J., Pedersen, R., Mele, L., Shen, Q., & Vlahos, B. (2017). Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PloS one, 12(6), e0179308. https://doi.org/10.1371/journal.pone.0179308
Moots, Robert J, et al. "Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study." PloS one vol. 12,6 (2017): e0179308. doi: https://doi.org/10.1371/journal.pone.0179308
Moots RJ, Xavier RM, Mok CC, Rahman MU, Tsai WC, Al-Maini MH, Pavelka K, Mahgoub E, Kotak S, Korth-Bradley J, Pedersen R, Mele L, Shen Q, Vlahos B. Correction: The impact of anti-drug antibodies on drug concentrations and clinical outcomes in rheumatoid arthritis patients treated with adalimumab, etanercept, or infliximab: Results from a multinational, real-world clinical practice, non-interventional study. PLoS One. 2017 Jun 05;12(6):e0179308. doi: 10.1371/journal.pone.0179308. eCollection 2017. PMID: 28582423; PMCID: PMC5459555.
Copy
Download .nbib
